Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | December 31, 2022 | February 03, 2023 |
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director · Chief Executive Officer | December 21, 2021 | December 23, 2021 |
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 03, 2026 | June 05, 2026 |
| Hemab Therapeutics Holdings, Inc.COAG · Entity 4476 | Director | January 29, 2026 | May 04, 2026 |
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Director | June 24, 2026 | June 25, 2026 |
| PROKIDNEY CORP.PROK · Entity 5181 | Director | June 29, 2023 | July 03, 2023 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662 | Director | July 01, 2026 | July 06, 2026 |
| bluebird bio, Inc.BLUE · Entity 78923 | Director | September 14, 2017 | September 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date December 31, 2022 · Filed February 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 28,528 |
Reported balance
After 2022-09-20 transaction · row 1
1 source rowRow 1 · 2022-09-20 · Gift · Disposed 1,500 · Balance 28,528 F1: This disposition reflects a bona fide gift of 1,500 shares to charity. |
Filing footnotes · ownership attribution and instrument terms
F1: This disposition reflects a bona fide gift of 1,500 shares to charity.
ALNYLAM PHARMACEUTICALS, INC.
Report date December 21, 2021 · Filed December 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 227,663 |
Ending reported balance
After 2021-12-22 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-12-21 · Grant · Acquired 14,167 · Balance 234,299 F1: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021. Row 2 · 2021-12-22 · Tax withholding · Disposed 6,315 · Balance 227,984 F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Row 3 · 2021-12-22 · Tax withholding · Disposed 2 · Balance 227,982 F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. Row 4 · 2021-12-22 · Tax withholding · Disposed 319 · Balance 227,663 F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 3,133 |
Reported balance
Holding disclosure · report date 2021-12-21 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,133 F3: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021.
F2: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.
F3: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
Beam Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.55 · Expires 2036-06-03 | Direct | 19,676 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 19,676 · Balance 19,676 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Hemab Therapeutics Holdings, Inc.
Report date January 29, 2026 · Filed May 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,948 |
Ending reported balance
After 2026-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-04 · Conversion · Acquired 17,974 · Balance 17,974 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. Row 2 · 2026-05-04 · Conversion · Acquired 17,974 · Balance 35,948 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2036-01-28 | Direct | 107,338 |
Reported balance
After 2026-01-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-29 · Grant · Acquired 107,338 · Balance 107,338 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-04 · Conversion · Disposed 817 · Balance 0 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. F2: Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-04 · Conversion · Disposed 817 · Balance 0 F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029. F2: Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029.
F2: Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Kymera Therapeutics, Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.87 · Expires 2036-06-23 | Direct | 6,068 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 6,068 · Balance 6,068 F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.
PROKIDNEY CORP.
Report date June 29, 2023 · Filed July 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 · Expires 2033-06-29 | Direct | 48,128 |
Reported balance
After 2023-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-29 · Grant · Acquired 48,128 · Balance 48,128 F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted under the Issuer's non-employee director compensation policy.
F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
TAKEDA PHARMACEUTICAL CO LTD
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,400 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 3,800 · Balance 10,400 F1: Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029. F2: Reflects the conversion of 3,100 Ordinary Shares into 6,200 American Depositary Shares upon vesting of RSUs. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2026-06-01 | Direct | 0 |
Reported balance
After 2026-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-10 · Disposition to issuer · Disposed 1,152 · Balance 0 F3: Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10. F4: The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,883 to JPY 5,045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2029-06-01 | Direct | 1,319 |
Reported balance
After 2026-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-01 · Grant · Acquired 1,319 · Balance 1,319 F5: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. |
| American Depositary SharesSEC Table I · non-derivative | Direct | 13,800 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 13,800 F2: Reflects the conversion of 3,100 Ordinary Shares into 6,200 American Depositary Shares upon vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029.
F2: Reflects the conversion of 3,100 Ordinary Shares into 6,200 American Depositary Shares upon vesting of RSUs.
F3: Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10.
F4: The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,883 to JPY 5,045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
bluebird bio, Inc.
Report date September 14, 2017 · Filed September 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,843 |
Ending reported balance
After 2017-09-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-09-14 · Exercise / conversion · Acquired 18,868 · Balance 24,711 Row 2 · 2017-09-14 · Sale · Disposed 18,268 · Balance 6,443 F1: The range in prices for the transaction reported on this line was $130.80 to $131.75. The average weighted price was $131.1935. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2017-09-14 · Sale · Disposed 600 · Balance 5,843 F2: The range in prices for the transaction reported on this line was $131.80 to $131.90. The average weighted price was $131.8167. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.09 · Expires 2022-01-08 | Direct | 0 |
Reported balance
After 2017-09-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-09-14 · Exercise / conversion · Acquired 18,868 · Balance 0 F3: This option vests in 48 equal monthly installments, commencing on April 1, 2011. |
Filing footnotes · ownership attribution and instrument terms
F1: The range in prices for the transaction reported on this line was $130.80 to $131.75. The average weighted price was $131.1935. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2: The range in prices for the transaction reported on this line was $131.80 to $131.90. The average weighted price was $131.8167. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: This option vests in 48 equal monthly installments, commencing on April 1, 2011.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2017 Filed Jun 12, 2017 20:58 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $111.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039205 · doc4.xml · derivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: CommonStock · 4,000 shares Expires 2027-06-08 F2 · derivative.exercise_date: This option vests 100% on the earlier of June 8, 2018, or the date of the next annual meeting of stockholders. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:58 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039205 · doc4.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,843 F1 · security: These restricted stock units for common stock vest 100% on the earlier of June 8, 2018, or the date of the next annual meeting of stockholders. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:24 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 12,917 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001209191-17-018411 · doc4.xml · derivative · entry 5 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,917 shares Expires 2023-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 16, 2014 and in 36 equal monthly installments thereafter. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:24 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionStock Option (right to buy) · Derivative | 922 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001209191-17-018411 · doc4.xml · derivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 922 shares Expires 2020-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests over a one-year period, at a rate of twenty-five percent (25%) on December 6, 2010, 25% on March 6, 2011, 25% on June 6, 2011, and 25% on September 6, 2011. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:24 UTC | bluebird bio, Inc. BLUE · Entity 78923 | SaleCommon Stock | 13,839 | $85.02 | $1,176,645.75 |
DisclosureSEC source: 0001209191-17-018411 · doc4.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,843 F1 · price: The range in prices for the transaction reported on this line was $84.50 to $85.35. The average weighted price was $85.0239. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:24 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 12,917 | $5.50 | $71,048.67 |
DisclosureSEC source: 0001209191-17-018411 · doc4.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:24 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Exercise / conversionCommon Stock | 922 | $0.95 | $874.42 |
DisclosureSEC source: 0001209191-17-018411 · doc4.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,340 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0001553878-17-000002 · primary_doc.xml · derivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,641 Underlying: Common Stock · 1,340 shares Expires 2022-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,340 | $18.66 | $25,004.40 |
DisclosureSEC source: 0001553878-17-000002 · primary_doc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 21:19 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001325812-16-000105 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-20 F1 · shares: Represents the time-vested portion of the reporting person's 2016 Annual Stock Option award. The reporting person also received an option to purchase 25,000 shares of ALNY common stock that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the option vests. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 20, 2016 Filed Jan 23, 2017 21:02 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GiftCommon Stock | 1,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-005067 · doc4.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,843 F1 · balance_after: Takes into account 5,293 shares previously acquired and included on the Form 4 filed on December 22, 2014 by the reporting person. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 30,151 | $0.00 Strike: $22.75 | $0.00 |
DisclosureSEC source: 0001325812-16-000097 · primary_doc.xml · derivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,151 shares Expires 2016-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents a "net exercise" of outstanding stock options due to expire on December 14, 2016, as permitted under the governing ALNY stock incentive plan. These shares were withheld by ALNY for payment of the option exercise price and applicable tax withholding, based on the closing price of ALNY common stock on December 12, 2016. F3 · derivative.exercise_date: The stock option vested as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Tax withholdingCommon Stock | 22,710 | $42.61 | $967,673.10 |
DisclosureSEC source: 0001325812-16-000097 · primary_doc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,370 F1 · kind: Represents a "net exercise" of outstanding stock options due to expire on December 14, 2016, as permitted under the governing ALNY stock incentive plan. These shares were withheld by ALNY for payment of the option exercise price and applicable tax withholding, based on the closing price of ALNY common stock on December 12, 2016. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 30,151 | $22.75 | $685,935.25 |
DisclosureSEC source: 0001325812-16-000097 · primary_doc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents a "net exercise" of outstanding stock options due to expire on December 14, 2016, as permitted under the governing ALNY stock incentive plan. These shares were withheld by ALNY for payment of the option exercise price and applicable tax withholding, based on the closing price of ALNY common stock on December 12, 2016. Read SEC document |
| October 12, 2016 Filed Oct 14, 2016 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,019 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0001553878-16-000057 · primary_doc.xml · derivative · entry 5 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,981 Underlying: Common Stock · 4,019 shares Expires 2022-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| October 12, 2016 Filed Oct 14, 2016 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,521 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001553878-16-000057 · primary_doc.xml · derivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,915 Underlying: Common Stock · 3,521 shares Expires 2021-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| October 12, 2016 Filed Oct 14, 2016 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 4,019 | $18.66 | $74,994.54 |
DisclosureSEC source: 0001553878-16-000057 · primary_doc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2016 Filed Oct 14, 2016 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 3,521 | $7.10 | $24,999.10 |
DisclosureSEC source: 0001553878-16-000057 · primary_doc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.